Prostate cancer is the most prevalent cancer and the second leading cause of cancer death among males. In the United States in 2012, an estimated 241 740 new cases of prostate cancer and 28 170 deaths from prostate cancer were reported ([@bib31]). Normal prostate tissue comprises gland units, in which epithelial cells polarise in the apical--basal direction and align into lumen or tubular structures to facilitate secretion ([@bib22]; [@bib35]). This polarised cell organisation maintains proper organ function and regulates cell proliferation. Disturbance of this normal tissue organisation and cell polarity is a hallmark of malignancy ([@bib1]; [@bib5]).

Cell polarisation is also essential for cell migration, with a front--rear axis driving cell movement in response to extracellular signals. In the leading edge of a migrating cell (facing the direction of movement), the actin cytoskeleton is reorganised to form membrane ruffling or spike-like filopodia. At the back of the migrating cell, the nucleus localises oriented towards the leading edge, with the microtubule-organising centre (MTOC) and Golgi apparatus positioned in front of the nucleus ([@bib28]; [@bib5]).

In epithelial polarity regulation, there are three crucial polarity protein complexes: Par/aPKC, Crumbs, and Scribble. The Par complex -- including Par3, Par6, Cdc42, and atypical protein kinase C (aPKC) -- is a master regulator of apical--basal polarity, which is involved in almost all metazoan cells. Par6 exists in three mammalian Par6 isoforms (A, B, and C) with conserved protein-interaction domains. The Phox/Bem1 (PB1) domain localises at the N-terminus of Par6 and binds to other PB1 domain-containing proteins (e.g., aPKC), while the C-terminus of Par6 harbours the PSD-95/Dlg/ZO-1 (PDZ) domain that binds Par3. The middle of Par6 contains the Cdc42--Rac interaction binding (CRIB) motif, which binds the Cdc42 or Rac GTPases. Par3 localises in tight junctions at the apical--lateral border, providing anchorage for the Par complex ([@bib14]; [@bib16]). Par6 functions as a scaffolding protein for Par complex assembly by direct interaction with Par3, aPKC, and Cdc42/Rac1 at the apical--lateral border. Under normal conditions, Par complexes localise in cell junctions to maintain epithelial cell--cell contacts and cell polarity. In neuronal cells, the polarity complex is required for initial axon formation and is recruited to the axon tip in a manner dependent on phosphoinositide 3-kinase (PI3K) ([@bib30]). In cancer cells, mislocalisation and high expression of polarity proteins are reportedly related to cancer progression ([@bib29]; [@bib7]; [@bib1]).

TGF*β* regulates different cellular processes -- including cell migration, proliferation, differentiation, apoptosis, and epithelial--mesenchymal transition (EMT) ([@bib20]; [@bib13]) -- and activates downstream signalling pathways via its type I and type II serine/threonine kinase receptors. For the canonical Smad signalling pathway, TGF*β* first binds the constitutively active TGF*β* type II receptor (T*β*RII) and then recruits and phosphorylates the GS domain of the TGF*β* type I receptor (T*β*RI). This activates the T*β*RI kinase domain, which in turn phosphorylates Smad2/Smad3 ([@bib8]; [@bib21]). TGF*β* also activates non-Smad pathways, including the p38/JNK MAPK pathway, Rho-like GTPase signalling pathway, PI3K--AKT--mTOR pathway, and Ras--Erk--MAPK pathway ([@bib23]; [@bib24]).

Par6 interacts with the TGF*β* receptor complex and is phosphorylated upon TGF*β* stimuli ([@bib34]; [@bib26]; [@bib2]). Phosphorylated Par6 has a crucial role in TGF*β*-induced EMT, which is reportedly related to breast cancer progression ([@bib33]). Sustained TGF*β* receptor signalling has also been observed in prostate cancer ([@bib25]), but its role remains unclear.

In the present study, we investigated whether p-Par6 is involved in TGF*β*-induced migratory responses in prostate cancer cells. Our results showed that TGF*β* induced Par6 phosphorylation, and in turn, p-Par6 formed a complex with aPKC at the leading edge of membrane ruffles, which was important for migration and invasion of prostate cancer cells. Interestingly, prostate cancer cell invasion could be prevented by interfering with polarity complex formation. Moreover, analysis of Par6 signalling in prostate cancer cells and tissues revealed that high levels of p-Par6 correlated to prostate cancer progression.

Materials and methods
=====================

Cell culture
------------

The human prostate cancer cell line PC-3U originated from PC-3 ([@bib9]), grown in RPMI-1640 with 10% foetal bovine serum (FBS) and L-glutamine. The human immortalised normal prostate cell line RPWE1 were purchased from ATCC (Manassas, VA, USA), grown according to the manufacturer\'s recommendation in Keratinocyte Serum-Free Medium with bovine pituitary extract and human recombinant epidermal growth factor (GIBCO).

Antibodies and reagents
-----------------------

The rabbit polyclonal p-Par6 antibody was produced in our laboratory and its specificity was tested. For immunoblotting or immunofluorescence staining, we purchased antibodies against Par6 from Abcam (Cambridge, UK), p-PKC*ζ*(H2) and N-cadherin from Santa Cruz Biotechnology (Dallas, TX, USA), E-cadherin from BD Biosciences (Franklin Lakes, NJ, USA), and antibodies against PARD6B(HPA), PKC*ζ*(HPA), *β*-actin, and *β*-tubulin from Sigma Aldrich (St Louis, MO, USA). Rabbit anti-phospho-Smad2 antiserum was generated in-house and described previously ([@bib27]). We purchased 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) from Merk (Rahway, NJ, USA), TRITC-labelled phalloidin from Sigma Aldrich; Alexa Fluor 488 and Alexa Fluor 555 from Invitrogen (Carlsbad, CA, USA); LumiLight western blotting substrate and Pefabloc from Roche Diagnostics (Indianapolis, IN, USA); the PageRuler prestained protein ladder from Fermentas (Waltham, MA, USA), and PKC*ζ* pseudosubstrate from Tocris Bioscience (Ellisville, MO, USA).

Western blotting
----------------

Cells were grown on 10-cm dishes. After 12--18 h of starvation in medium supplemented with 1% FBS, the indicated inhibitors were added into the media. One hour later, the cells were stimulated with TGF*β*1 10 ng ml^−1^ (R&D System, Minneapolis, MN, USA) for 30 min. Next, the cells were washed once with ice-cold PBS and lysed in ice-cold lysis buffer containing 150 m[M]{.smallcaps} NaCl, 50 m[M]{.smallcaps} Tris (pH 8.0), 0.5% (v/v) DOC, 1% (v/v) NP40, 10% (v/v) glycerol, 1 m[M]{.smallcaps} aprotinin, 1 m[M]{.smallcaps} Pefabloc, and 2 m[M]{.smallcaps} sodium orthovanadate. After centrifugation, the supernatants were collected and protein concentrations were determined using the BCA Protein Measurement Kit (Nordic Biolabs, Täby, Sweden). Equal amounts of protein from the total cell lysate were run in SDS--PAGE and transferred onto polyvinylidine difluoride membranes. The membranes were blocked for 1 h with 5% BSA in TBS-Tween, followed by overnight incubation at 4 °C with primary antibody. Then the membranes were washed three times with TBS-Tween, incubated for 1 h with a secondary horseradish peroxidase-conjugated antibody, and developed with LumiLight PLUS Western Blot Substrate (Roche Diagnostics).

Western blotting using the fluorescence-based LI-COR detection system
---------------------------------------------------------------------

The proteins were transferred to polyvinylidine difluoride membranes, which were then blocked for 1 h with 20 ml of Odyssey blocking solution, followed by overnight incubation at 4 °C with specific antibodies. The next day, the membranes were washed three times with TBS-Tween, followed by a 1-h incubation with IRDye 680RD or 800CW secondary antibodies (LI-COR Bioscience, Lincoln NE, USA) at room temperature. Finally, the membranes were rinsed three times with TBS-Tween and scanned using the infrared imaging scanner (Odyssey CLx Imager; LI-COR Bioscience).

Immunofluorescence staining for cultured cells
----------------------------------------------

Wound-healing assays were performed on serum-starved confluent cells growing on sterile glass microscopy cover slides in six-well plates without coating, by using a 1000-*μ*l pipette tip for scratching. Control cells and migrating cells facing the wound were subjected to immunofluorescence analyses of cytoskeletal rearrangements by actin stainings (phalloidin, which stains F-actin), or for analysis of subcellular localisation of proteins, as indicated in the figure legends. The slides were washed four times with PBS and then fixed in 4% paraformaldehyde for 30 min at room temperature. Next, they were washed four times in PBS and subsequently permeabilised in 0.1% Triton X-100 in PBS for 5 min. After four more washes in PBS, the slides were blocked overnight in 10 m[M]{.smallcaps} glycine. The next day, the slides were incubated at room temperature for 1 h in a humid chamber with the primary antibodies. After washing with PBS, the slides were incubated with fluorescent dye-labelled secondary antibodies for 45 min at room temperature, followed by 5-min incubation with DAPI. Thereafter, the mount medium was added on the slides for imaging. The samples were analysed at room temperature using a fluorescence microscope (Axioplan 2; Carl Zeiss Microimaging, Inc., San Diego, CA, USA) with a digital camera (C4742-95; Hamamatsu, Shizuoka, Japan), using a Plan-neofluar × 63 objective lens (Carl Zeiss MicroImaging, Inc.). The primary images were acquired using the camera\'s QED software. The analyses of F-actin reorganisation in membrane ruffles and analyses of p-Par6 localisation in membrane ruffles were performed three times and approximately 200--300 cells facing the wound were counted under the microscope in each experiment.

Invasion assay
--------------

An invasion assay was performed using the CytoSelect Cell Invasion Assay kit (Cell Biolabs, Inc., San Diego, CA, USA). The collagen layer of the cell culture inserts was rehydrated in 300 *μ*l serum-free RPMI-1640 media. Then 1 × 10^6^ cells were seeded on the upper side of the chambers in 1% serum RPMI-1640 with or without TGF*β* and in the absence or presence of inhibitors. The lower wells of the invasion plates were filled with 500 *μ*l RPMI with 10% FBS. Non-invasive cells were removed from the upper chamber, and the invasive cells were photographed with a Leica (Wetzlar, Germany) DMR light microscope after staining with crystal violet cell stain solution. Colorimetric quantification was performed by transferring the inserts into 200 *μ*l of extraction solution for 10 min. Optical density (OD) at 560 nm was measured in a 96-well plate using a Multiskan FC Microplate Photometer (Thermo Scientific, Waltham, MA, USA). Statistical analyses were performed using the SPSS software (Chicago, IL, USA), and *P*-values were calculated by one-way ANOVA.

Immunofluorescent staining of paraffin-embedded sections
--------------------------------------------------------

Paraffin-embedded sections of prostate cancer tissue were kindly provided by the Department of Immunology, Genetics and Pathology of the Uppsala University Hospital. Ethical permission to use decoded tumour tissues to generate tissue slides was granted by the Uppsala ethical review board in full agreement with the Swedish Ethical Review Act. The sections were rehydrated twice in xylene for 10 min each; then in 100% ethanol for 10 min; followed by 5-min incubations in 95, 80, and 70% ethanol and deionised H~2~O; and finally in PBS for 10 min. Thereafter, the sections were treated with Antigen Retrieval Reagent (R&D) at 95 °C for 5 min, rinsed with PBS, blocked in 1% horse serum in PBS for 1 h at room temperature, and then incubated with primary antibodies overnight at 4 °C. After three 5-min washes with PBS, the sections were incubated with NorthernLights secondary antibody (R&D) for 45 min at room temperature. Finally, the sections were subjected to three more 5-min washes with PBS and then mounted with mounting media with DAPI and visualised using a fluorescence microscope (Axioplan 2; Carl Zeiss Microimaging, Inc.).

Tissue microarray (TMA) preparation from whole mounts of prostatectomy specimens and staining procedure
-------------------------------------------------------------------------------------------------------

Prostatectomy specimens were obtained from a cohort of 127 patients operated between 1993 and 2002 at the Department of Urology and collected at the Department of Pathology, University Hospital, Uppsala, Sweden. Ethical permission to use decoded tumour tissues for the generation of tissue slides was granted by the Uppsala ethical review board in full agreement with the Swedish Ethical Review Act. From each specimen, the transverse section including the cancerous area with the most representative global Gleason score (GS) was used for TMA preparation. From each case, we took three 1-mm punches from such areas, along with one punch from normal prostate tissue. All cases were carefully reviewed regarding the extent and grade and the representativeness of the punches.

The sections were deparaffinised and retrieved in the above-described manner. Thereafter, the sections were incubated in 3% H~2~O~2~/methanol for 10 min, washed twice with PBS, and blocked in 5% normal goat serum for 1 h at room temperature. The sections were then incubated overnight at 4 °C with p-Par6 antibody and with normal rabbit IgG as a negative control. After three 5-min washes with PBS, the sections were incubated with secondary antibody (K4065; DAKO envision system, Glostrup, Denmark) for 45 min at room temperature. After three more washes in PBS, the sections were developed with AEC (SK-4200; Vector Laboratories, Burlingame, CA, USA) and mounted in aqueous mounting medium (H-5501; Vector Laboratories).

Quantitative assessment
-----------------------

Digital images of TMA sections were acquired by scanning with a Panoramic 250 Flash II (3DHistech, Ramsey, NJ, USA) and analysed using the ImageJ software (Lexington, KY, USA). Grey-scale values (pixel intensities) within the regions of interest were measured, and the minimum, maximum, and mean pixel intensity values were calculated to compare the intensities of immunoperoxidase reaction. From each group, we calculated the mean±s.e.m., and Student\'s *t* tests were used to evaluate the between-group differences.

Results
=======

TGF*β*-induced p-Par6Ser^345^ in the leading edge of polarised prostate cancer cells
------------------------------------------------------------------------------------

[@bib26] reported that the TGF*β* type II receptor (T*β*RII) phosphorylates the C-terminus of Par6 at residue Ser^345^, which is important for TGF*β*-induced dissolution of tight junctions during EMT. As there is no commercially available phospho-specific antibody for detection of p-Par6, we generated rabbit polyclonal antibodies against p-Par6Ser^345^ in-house. To verify the specificity of this antibody, Flag-tagged wild-type Par6 or the non-phosphorylated Par6 mutant Flag-tagged Par6Ser345Ala was expressed in human prostate cancer cells (PC-3U), followed by immunoblotting of p-Par6, total Par6, and Flag ([Figure 1A](#fig1){ref-type="fig"}). As expected, we observed a TGF*β*-induced phosphorylation of the ectopically expressed WT Par6 but not of the Ser345Ala mutant Par6, thus confirming the specificity of the p-Par6Ser^345^ antibody. Use of the fluorescence-based LI-COR detection system enabled detection of p-Par6Ser^345^ together with Par6 and Flag antibodies. Similar results were obtained in human embryonic kidney (HEK) 293T cells ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

Cell migration requires formation of cell protrusion called membrane ruffling and the formation of a polarised structure characterised by actin and microtubule polymerisation ([@bib28]; [@bib4]; [@bib3]). Par6 is the major scaffolding protein enabling Par complex assembly and thus cell polarity regulation. Hence, it is likely that Par6 phosphorylation may affect the subcellular localisation and function of the polarity complex. Therefore, we next investigated the subcellular localisation of p-Par6Ser^345^ in a wound-healing assay, in which TGF*β* was used to stimulate PC-3U cells to migrate to cover a wounded area ([Figure 1B](#fig1){ref-type="fig"}). Immunofluorescence imaging showed that TGF*β* induced p-Par6Ser^345^ localisation in the membrane ruffles of the leading edge of migrating cells and bound to the cytoskeleton to direct cell migration towards the wound ([Figure 1B](#fig1){ref-type="fig"}). We also quantified the effects of TGF*β*-induced membrane ruffling in PC-3U cells subjected to wound-healing assays, as described above. A significant increase in membrane ruffling was noted in cells treated with TGF*β*, when compared with control cells ([Figure 1C](#fig1){ref-type="fig"}). These data are in line with our and other previous observations of T*β*RI localisation in the leading edge of migrating cells ([@bib32]; [@bib3]). This finding suggests that TGF*β* regulates the localisation of p-Par6 to the leading edge of migrating prostate cancer cells. Together, our data indicate that phosphorylation of Par6 at Ser^345^ and its recruitment to the leading edge of migrating cells is dependent on TGF*β*.

TGF*β*-induced formation of the p-Par6--aPKC complex in migrating prostate cancer cells
---------------------------------------------------------------------------------------

Par6 is a key adaptor protein for Par complex assembly through interactions with Par3, atypical PKC, and Cdc42/Rac1. Therefore, we further investigated whether a Par6--PKC complex could be formed in the frontier of migrating cells. Co-immunofluorescence staining in the wound-healing assay revealed TGF*β*-induced co-localisation of p-Par6 and p-PKC*ζ* in the membrane ruffles of the leading edge of migrating PC-3U cells ([Figure 2A](#fig2){ref-type="fig"}).

The Par complex further recruits Cdc42 to form a large protein complex that orients the MTOC and regulates cell polarity ([@bib5]); therefore, we further investigated the interaction between Par complexes and microtubules. Co-immunofluorescence analysis showed that p-Par6 localised exactly at the front tip of the polarised microtubule, with a tight connection to the polarised microtubules ([Figure 2B](#fig2){ref-type="fig"}). From these data, we concluded that TGF*β* treatment led to Par6 phosphorylation and formation of the p-Par6--aPKC complex in the frontier of membrane ruffling, which is connected to the polarised microtubules to orient the MTOC and direct cell migration. However, the molecular mechanism for the involvement of the Par6 complex in orienting the MTOC must be further investigated.

Disturbance of the p-Par6--aPKC*ζ* complex prevents invasion of prostate cancer cells
-------------------------------------------------------------------------------------

The p-Par6--aPKC complex is important in regulating cell polarity and cell migration, inspiring us to investigate whether interfering with the p-Par6--aPKC complex could prevent cell migration. An invasion assay demonstrated that PC-3U cells invaded the lower chamber upon 36 h of TGF*β* treatment. As expected, PC-3U cell invasion was blocked by treatment with the PKC*ζ*-specific inhibitor, PKC*ζ* pseudosubstrate (PKC*ζ* PS), or the PI3K inhibitor LY294002 ([Figure 3A](#fig3){ref-type="fig"}). Colorimetric quantification followed by statistical analysis revealed that the invasive capability of the PC-3U cells dramatically decreased following the use of these inhibitors ([Figure 3B](#fig3){ref-type="fig"}). This suggests that inhibitors of the p-Par6Ser^345^ pathway could prevent invasion of aggressive prostate cancer cells.

Enhanced expression of p-Par6 and PKC in prostate cancer
--------------------------------------------------------

To explore the role of p-Par6 in human prostate cancer, we analysed the expression levels and localisations of p-Par6 and PKC*ζ* in prostate cancer tissue. A control experiment using only secondary antibodies verified the specificity of the antibodies in our study ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Normal prostate tissue showed low levels of p-Par6 and high levels of PKC*ζ* ([Figure 4A](#fig4){ref-type="fig"}). Both proteins localised in the apical plasma membrane toward the secretary lumen, as well as in the cell tight junction in the lateral and basolateral plasma membrane. This localisation is important for maintaining the cell--cell junction and thus regulating apical--basal polarity under physiological conditions. Interestingly, prostate cancer tissue showed dramatically increased p-Par6 expression and slightly decreased PKC*ζ* expression ([Figure 4B](#fig4){ref-type="fig"}). These polarity proteins were highly expressed in the invasive front where prostate cancer cells aggressively invaded into the adjacent mesenchymal tissue ([Figure 4C](#fig4){ref-type="fig"}). This finding indicates that enhanced expression and localisation of p-Par6 and PKC*ζ* is related to prostate cancer invasiveness.

p-Par6 expression levels in prostate tissue and clinical correlation
--------------------------------------------------------------------

To confirm the potential role of p-Par6 as a predictive biomarker, we analysed p-Par6 expression by using immunohistochemical staining in TMA sections from 127 prostate cancer samples, including 50 samples of adjacent normal prostatic tissue, 21 samples with GS\<7, 26 samples with GS=7, and 30 samples with GS⩾7. [Figure 5A](#fig5){ref-type="fig"} shows representative images of p-Par6 expression. In normal prostate tissue, low levels of p-Par6 were detected in the glandular epithelium and strictly localised in the apical membrane towards the lumen and the basolateral border ([Figure 5A](#fig5){ref-type="fig"}). In contrast, samples of intermediate-grade (GS\<7) and high-grade prostate cancer (GS⩾7) showed increased p-Par6 expression throughout the malignant epithelium. Interestingly, the p-Par6 level corresponded with the volume of malignant epithelium. Furthermore, p-Par6 expression was dramatically increased in poorly differentiated carcinoma where cancer cells proliferated and invaded into glandular lumens and the surrounding mesenchymal tissue (GS⩾7) ([Figure 5A](#fig5){ref-type="fig"}). [Figure 5B](#fig5){ref-type="fig"} presents the average grey-scale values for intensity of immunohistochemical staining for p-Par6, showing a significant greater p-Par6 expression in tumour samples compared with normal tissue samples (*P*\<0.05).

As we observed increased expression levels of p-Par6 in aggressive prostate cancer tissues, we further investigated the amounts of p-Par6 in androgen-independent and aggressive PC-3U cells compared with immortalised normal prostate RWPE1 cells. Immunoblotting of total cell lysates from TGF*β*-stimulated cells showed higher basal activity of p-Par6 and a TGF*β*-induced response only in PC-3U cells and not in RWPE1 cells ([Figures 5C and D](#fig5){ref-type="fig"}). E-cadherin is a crucial component to maintain epithelial intracellular adhesion, and its expression is downregulated during TGF*β*-induced EMT ([@bib13]). Loss of E-cadherin expression and increased N-cadherin expression is observed during prostate cancer progression ([@bib11]) and EMT in mammary cells ([@bib18]). Therefore, we also examined the expression of these adhesion molecules in the two cell lines. The expression of E-cadherin was reduced in PC-3U cells when compared with RWPE1 cells, and a TGF*β*-induced increase of N-cadherin was observed only in PC-3U cells ([Figure 5C](#fig5){ref-type="fig"}). TGF*β*-induced phosphorylation of Smad2 was observed in both the cell lines ([Figure 5C](#fig5){ref-type="fig"}). Immunofluorescence imaging showed a decrease in staining of E-cadherin in PC-3U cells, while in RWPE1 cells E-cadherin was found to be localised in cell--cell contacts ([Figure 5E](#fig5){ref-type="fig"}). Moreover, only in PC-3U cells, there was an increase of immunofluorescence staining of N-cadherin, in response to TGF*β* ([Figure 5E](#fig5){ref-type="fig"}), suggesting that PC-3U cells have a mesenchymal phenotype. These findings suggested that p-Par6 is correlated to the switch in E-cadherin and N-cadherin expression in prostate cancer cells. From these data, we conclude that p-Par6 could be a useful biomarker for aggressive prostate cancer.

Discussion
==========

In this study, we investigated whether TGF*β*-induced p-Par6 signalling promoted migration and invasion in prostate cancer cells. We observed that TGF*β*-induced Par6 activation was crucial for its localisation in the leading edge of membrane ruffles in the migrating cells. In turn, such localisation was important for formation of the p-Par6--aPKC*ζ* complex that connects to the microtubule system and directs cell migration. We detected high levels of p-Par6 signalling in prostate cancer tissue, which was associated with high GS as well as in aggressive PC-3U cells but not in immortalised normal prostate (RWPE1) cells. We also found that PKC*ζ* inhibition prevented prostate cancer cell invasion, indicating that the p-Par6--aPKC complex may be a novel target for therapeutic intervention in prostate cancer.

These findings provide functional evidence for the role of p-Par6 in tumour progression of prostate cancer cells.

We previously reported that Smad7 (a direct target gene for TGF*β*) and adenomatous polyposis coli (APC) mediate TGF*β*-induced migration of prostate cancer cells. We also found that Smad7 facilitates TGF*β*-induced phosphorylation of p38 and GSK-3*β*, resulting in GSK-3*β* inactivation and *β*-catenin accumulation and, in turn, APC recruitment to the microtubule plus end in the leading edge to direct cell migration ([@bib6]; [@bib3]). Furthermore, GSK-3*β* is a substrate for aPKC, and inhibitory phosphorylation of GSK-3*β* by aPKC induces APC recruitment to the microtubule plus end of migrating cells ([@bib6]). TGF*β* activates PKC*ζ* in prostate cancer cells, which is important for the cleavage and nuclear translocation of T*β*RI ([@bib25]). Here we observed Par6 phosphorylation in response to TGF*β* stimuli, followed by recruitment to the leading edge of migrating prostate cancer cells. The localisation of p-Par6 is important for formation of the p-Par6--p-PKC*ζ* complex in the membrane ruffles, where it connects to the microtubule system in migrating cells, potentially aiding in cell directional migration. It remains unclear whether p-Par6 is implicated in PKC*ζ* activation or has a role in GSK-3*β* inactivation in prostate cancer cell migration. Further studies are needed to answer these questions.

Phosphorylation of Par6 on serine^345^ has an important role in TGF*β*-induced EMT. In mammary gland epithelial cells, Par6 phosphorylation by TGF*β* type II receptor recruits Smurf1 (an E3 ubiquitin ligase) to target RhoA for degradation, which causes tight junction dissolution and loss of cell polarity ([@bib34]; [@bib26]). Moreover, TGF*β*-induced p-Par6Ser^345^ has been implicated in cell polarity regulation. Interference with Par6 signalling blocks TGF*β*-induced loss of acini-like structure and protrusive invasion in mammary tumour cells, which has a crucial role in regulating EMT and metastasis in breast cancer progression ([@bib33]).

During preparation of this manuscript, it was reported that PKC*ζ* interacts with TGF*β* receptors through Par6 and that aPKC kinase activity is important for Par6 phosphorylation. Moreover, the association between p-Par6Ser^345^ and PKC*ζ* has a role in TGF*β*-induced EMT and cell migration in non-small cell lung cancer ([@bib12]). In our present study, TGF*β*--p-Par6 signalling linked PKC*ζ* and microtubules, thus regulating migration and invasion of prostate cancer cells. PC-3U cells origininate from a bone metastasis of prostate cancer, and these cells have already partially undergone EMT, consistent with the reduced expression of E-cadherin in this cell line ([Figure 5C](#fig5){ref-type="fig"}) ([@bib3]), but the cells undergo further mesenchymal transformation with TGF*β* treatment as an increasing expression of N-cadherin was detected ([Figure 5C and E](#fig5){ref-type="fig"}). Thus, either TGF*β*--p-Par6 signalling may function in targeting RhoA degradation and cell--cell junction dissolution in EMT or it could facilitate PKC*ζ* and microtubules in directing the migration of different cell types in a contextual manner in response to TGF*β*.

Polarity signalling contributes to cancer progression *in vivo*. High Par6 activity correlates with human breast cancer having basal subtype features ([@bib33]), and PKC*ζ* overexpression promotes the aggressive phenotype of human prostate cancer cells ([@bib36]). Interestingly, our present results showed that high levels of p-Par6Ser^345^ correlated with malignancy of human prostate cancer. Upregulation of polarity proteins and overactivation of polarity signalling could disrupt cell orientation and facilitate cell migration ([@bib5]). Moreover, polarity protein mislocalisation is crucial for initiation of invasion. Using a 3-D culture model with Madin--Darby canine kidney cells, ([@bib10]) verified that PI(4,5)P~2~ and PTEN strongly regulate the localisation of Cdc42 and aPKC to the apical plasma membrane to maintain the polarised lumen structure. Furthermore, reduced levels of PTEN, annexin 2, or Cdc42 lead to intracellular accumulation of Par6/aPKC and formation of abnormal lumens ([@bib19]). Consistent with these findings, our present results also showed mislocalisation of p-Par6 and PKC*ζ* in prostate cancer tissue. PTEN is frequently mutated and deleted in prostate cancer ([@bib15]; [@bib17]), which could lead to enhanced PI3K activity. It will be very interesting to investigate whether PTEN can counteract TGF*β*--p-Par6-mediated invasion in prostate cancer cells.

Overall, our present results indicate that TGF*β*--p-Par6 signalling is important for migration and invasion in prostate cancer cells. Further analysis of TGF*β*--p-Par6 signalling might lead to development of useful biological markers for prediction of prostate cancer progression.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![**TGF*β*-induced phosphorylation of Par6 at serine 345.** (**A**) PC-3U cells were transiently transfected with wild-type Flag-Par6 or mutant Flag-S345A, followed by treatment with TGF*β*, lysis, and immunoblotting for p-Par6Ser^345^, Par6, Flag, and *β*-tubulin. NT means the group of cells that were not transfected with plasmids as a negative control. Bar graphs showing relative levels of p-Par6Ser^345^ present the mean±s.d. from three independent experiments. \**P*\<0.05, Student\'s *t*-test. (**B**) In a cell culture wound-healing assay, PC-3U cells were treated with TGF*β* followed by fixation in 4% paraformaldehyde and immunofluorescence staining for p-Par6Ser^345^ and phalloidin. Arrows indicate membrane ruffles that formed towards the wound. Nuclei are stained with DAPI. Scale bar=20 *μ*m. (**C**) Analysis for TGF*β*-induced formation of membrane ruffles. Each column presents the mean±s.d. from three independent experiments in which around 200--300 cells were counted. \**P*\<0.05, Student\'s *t*-test.](bjc201571f1){#fig1}

![**TGF*β* induces formation of a p-Par6Ser^345^--p-PKC*ζ* complex that connects to polarised microtubules.** In a cell culture wound-healing assay, PC-3U cells were treated with TGF*β*, fixed in 4% paraformaldehyde, and subjected to co-immunofluorescence staining (**A**) for p-Par6Ser^345^ and p-PKC*ζ* and (**B**) for p-Par6Ser^345^ and *β*-tubulin. Arrows indicates membrane ruffles that formed towards the wound. Nuclei are stained with DAPI. Scale bar=20 *μ*m.](bjc201571f2){#fig2}

![**The p-Par6Ser^345^--p-PKC*ζ* complex is related to TGF*β*-induced invasion of PC-3U cells.** (**A**) In an invasion assay, PC-3U cells were treated with TGF*β* in the absence or presence of the PKC*ζ*-specific inhibitor PKC*ζ* pseudosubstrate (PKC*ζ* PS) or the PI3K inhibitor LY2940002. Cells were visualised by staining with crystal violet cell stain solution. (**B**) Mean values for optical density (OD) of invasive cells. Error bars represent s.d. from three independent experiments. \**P*\<0.05, one-way ANOVA.](bjc201571f3){#fig3}

![**Increased expression levels of p-Par6Ser^345^ and PKC*ζ* in human prostate cancer and at the tumour invasion front.** Representative images of p-Par6Ser^345^ and PKC*ζ* expression in (**A**) human normal prostate tissue and (**B**) prostate cancer tissues (**C**) invasive front, obtained by immunofluorescence staining. Nuclei are stained with DAPI.](bjc201571f4){#fig4}

![**p-Par6Ser^345^ expression in prostate cells and tissues and its clinical correlation.** p-Par6Ser^345^ expression was evaluated by immunohistochemical staining in tissue microarray cores (TMA) of human prostate cancer tissues. (**A**) Representative images of p-Par6Ser^345^ staining in normal prostate tissue, moderately differentiated prostatic adenocarcinoma with a Gleason score (GS) of 3+3 (GS\<7), prostatic adenocarcinoma with pseudoglandular morphology and GS of 4+3 (GS=7), and poorly differentiated prostatic adenocarcinoma with GS of 4+4 (GS\>7). (**B**) p-Par6Ser^345^ staining was quantified using ImageJ. Mean±s.e.m. of estimated grey-scale values obtained from the following groups: normal tissue (*n*=50), GS\<7 (*n*=21), GS=7 (*n*=26), and GS\>7 (*n*=30). \**P*\<0.05 for between-group differences, Student\'s *t*-tests. (**C**) The prostate cancer cell line PC-3U and the noncancerous prostate epithelial cell line RWPE1 were treated with TGF*β* as indicated, lysed, and immunoblotted as indicated. (**D**) Bar graphs showing relative levels of p-Par6Ser^345^ present the mean±s.d. from three independent experiments. \**P*\<0.05, Student\'s *t*-test. (**E**) PC-3U and RPWE1 cells were treated with TGF*β* followed by fixation in 4% paraformaldehyde and immunofluorescence staining for E-cadherin and N-cadherin. Nuclei were stained with DAPI. Scale bar=20 *μ*m.](bjc201571f5){#fig5}
